Alnylam Pharmaceuticals (ALNY): היקף יתרות המזומנים של החברה

The high scaling potential of RNAi therapy allows Alnylam Pharmaceuticals (ALNY) to maintain pricing power for orphan drugs. This chart in the GURU.Markets terminal illustrates the company's cash balance, where the 3.58 level reflects the latest values. The business is expanding its reach by targeting cardiac and genetic pathologies, while growing operating revenue ensures financial autonomy and reduces the debt load.
Alnylam Inc. (ALNY) - פילוחי מדדים ודוחות פיננסיים

Investors are verifying the issuer's financial stability by analyzing liquid reserves relative to market value. The amount of cash reflects the net cash on the balance sheet, allowing for an assessment of the margin of safety and the asset's degree of undervaluation. For Alnylam Pharmaceuticals (ALNY), this capital is critical for financing costly chemical waste disposal and laboratory modernization. Sufficient liquidity levels guarantee compliance with ESG standards without compromising the development of RNA therapeutics.